Biomedical literature, made navigable

Follow the entities shaping the evidence.

Discover articles through diseases, drugs, treatments, interventions, clinical instruments, institutions and funders extracted from the BMJ open corpus.

An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.

View all families

Organisations named as supporting, sponsoring, or funding research.

5,089 articles · 9,137 mentions Institutions

Universities, hospitals, research centres, networks, and public bodies.

11,350 articles · 22,378 mentions Drugs

Named medicines, compounds, vaccines, and pharmacological agents.

10,506 articles · 58,393 mentions Diseases

Named diseases, disorders, syndromes, injuries, and health conditions.

23,712 articles · 125,551 mentions Treatments

Clinical therapies and care approaches used to manage a condition.

7,227 articles · 16,644 mentions Interventions

Programmes, procedures, policies, and other actions being evaluated.

4,132 articles · 9,994 mentions Clinical instruments

Named questionnaires, scales, scores, indices, and other clinical outcome assessments.

945 articles · 1,957 mentions

29,499matching articles

244,054matching entity mentions

30popular entities listed

0%of mentions human-reviewed

Filter articles

Entity familyJournalContent resourceEvidence policyAutomated confidence floorArticles per pageReset filters

“Reviewed + threshold” includes every confirmed correction plus unreviewed proposals at or above the selected model score.

Matching articles

29,499 articles · page 198 of 2459

ReFIT study (reversing frailty in transplantation): protocol for a longitudinal study to assess clinical and biomedical changes in frailty through kidney transplantation

bmjopen · abstract · 2026-03-02 · 17 matching annotations

97.3%

kidney failure Frailty University of Queensland organ failure kidney transplantation

…lowing kidney transplantation. This makes younger patients with kidney failure a unique population for studying both the accelerated onset of …

LBA:01:31 Clinical spectrum, genetic background, and outcomes of pediatric monogenic lupus: a single-center cohort study

lupusscimed · abstract · 2026-03-01 · 17 matching annotations

99.4%

hydroxychloroquine monogenic lupus rituximab intensive care interventions lupus tertiary pediatric rheumatology center lupus-like JAK inhibitors JAK inhibitors biologic therapies+1 more

…C 2021 criteria, while nine met ILE criteria. During follow-up, hydroxychloroquine was used in 14 patients, csDMARDs in 9, JAK inhibitors in 10, a…

PO:01:015 Thromboangiitis obliterans in antiphospholipid syndrome and treatment

lupusscimed · abstract · 2026-03-01 · 17 matching annotations

98.6%

rituximab aspirin hydroxychloroquine alprostadil antiphospholipid syndrome peripheral arterial disease dry gangrene occlusive artery disease thromboangiitis obliterans thrombolysis+2 more

…t to standard anticoagulant therapy and requires treatment with rituximab with good effect.…

PO:02:057 Ficolin-3 activity correlates with disease activity, interferon-regulated chemokines and autoantibody profile in African SLE patients

lupusscimed · abstract · 2026-03-01 · 17 matching annotations

98.6%

Ficolin-3 SLE systemic lupus erythematosus

…autoantibodies (OR [95% CI] = 0.17 [0.03-0.86], p-value 0.032). Ficolin-3 associated positively with 10 inflammatory plasma proteins, int…

PO:03:076 Systemic lupus erythematosus and statins in GLADEL 2.0: are cardiovascular risk prevention guidelines being followed?

lupusscimed · abstract · 2026-03-01 · 17 matching annotations

95.5%

Statin therapy systemic lupus erythematosus ASCVD GLADEL 2.0 statin SLE atherosclerotic cardiovascular disease EULAR

…iovascular risk (CVR), following general population guidelines. Statin therapy plays a key role in reducing CVR and preventing ASCVD events. W…

PO:03:087 Bone mineral density (BMD) – a prospective evaluation of its impact on fractures and major adverse cardiovascular events (MACEs) in women with SLE

lupusscimed · abstract · 2026-03-01 · 17 matching annotations

97.4%

osteoporosis SLE ischemic heart disease osteopenia corticosteroid treatment arrythmia cerebrovascular disease aortic aneurysm

… haveosteoporosis, and 143 (44.1%) to have osteopenia. Baseline osteoporosis and osteopenia showed similar patterns of association: they wer…

PO:04:101 Recurrent lupus pneumonia successfully treated with anifrolumab: a case report

lupusscimed · abstract · 2026-03-01 · 17 matching annotations

98.7%

anifrolumab apixaban Prednisone warfarin Rituximab Systemic Lupus Erythematous SLE ACLE methylprednisolone Corticosteroid therapy

…thematous (SLE). We report a case of recurrent ALP treated with anifrolumab.Methods A 47-year-old man presented in August 2022 with progres…

PO:05:145 Attainment of remission or lupus low disease activity state in single center lupus clinic

lupusscimed · abstract · 2026-03-01 · 17 matching annotations

99.3%

SLE GC Lupus Clinic glucocorticoids

…45 Table 1Conclusions A substantial proportion of long-standing SLE achieved remission, associated with longer disease duration, lo…

PO:06:152 Can large language models support clinical decision-making in atypical SLE? A comparative analysis

lupusscimed · abstract · 2026-03-01 · 17 matching annotations

98.2%

mycophenolate mofetil hydroxychloroquine systemic lupus erythematosus SLE HCQ MMF corticosteroids

…whereas GPT suggested guideline-consistent alternatives such as mycophenolate mofetil (MMF) or hydroxychloroquine (HCQ). In one case, all models reco…

PO:06:154 Application of the SLERPI scoring system as a classification tool for systemic lupus erythematosus and its value for early disease recognition

lupusscimed · abstract · 2026-03-01 · 17 matching annotations

98.6%

SLE SLERPI Systemic Lupus Erythematosus

…the ACR/EULAR criteria. It may serve as a useful tool for early SLE identification, even when the control patients are ANA-positive…

PO:07:179 Benchmark-SLE: prospective observational study of standard of care efficacy and safety in active SLE with inadequate response to glucocorticoids and at least 2 immunosuppressants

lupusscimed · abstract · 2026-03-01 · 17 matching annotations

97.1%

Systemic lupus erythematosus SLE Benchmark-SLE GC lupus nephritis glucocorticoids SoC CA0611025 NCT07175285

…Objectives Systemic lupus erythematosus (SLE) is a chronic, immune-mediated disease that can affect mul…

PO:07:187 The incidence, mortality and complications of systemic lupus erythematosus: a population-level cohort study from 2012 to 2023

lupusscimed · abstract · 2026-03-01 · 17 matching annotations

91.6%

osteoporosis ischaemic heart disease interstitial lung disease fibromyalgia chronic kidney disease diabetes mellitus systemic lupus erythematosus cancer SLE

… chronic kidney disease (CKD), interstitial lung disease (ILD), osteoporosis, fractures, and cancer; fibromyalgia was additionally examined …